{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.1","upperLimit":"97.1","value":"86.4"},{"groupId":"OG001","lowerLimit":"70.8","upperLimit":"98.9","value":"90.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"IDCR is defined as the DCR based on lesions in brain (target, non-target lesions and new lesions, if applicable) and calculated as the percentage of patients with a best overall response of CR or PR or SD (or non-CR/nonPD) in the brain per modified RECIST 1.1 as assessed by BIRC neuro-radiologist.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Patients with measurable brain disease and who had a baseline and at least one post-baseline scan","reportingStatus":"POSTED","timeFrame":"Up to approximately 34 months","title":"Intracranial Disease Control Rate (IDCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}